|
1
|
Dion F, Mes-Masson AM, Seymour RJ,
Provencher D and Tonin PN: Allelotyping defines minimal imbalance
at chromosomal region 17q25 in non-serous epithelial ovarian
cancers. Oncogene. 19:1466–1472. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Foulkes WD, Black DM, Stamp GW, Solomon E
and Trowsdale J: Very frequent loss of heterozygosity throughout
chromosome 17 in sporadic ovarian carcinoma. Int J Cancer.
54:220–225. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Presneau N, Dewar K, Forgetta V,
Provencher D, Mes-Masson AM and Tonin PN: Loss of heterozygosity
and transcriptome analyses of a 1.2 Mb candidate ovarian cancer
tumor suppressor locus region at 17q25.1–q25.2. Mol Carcinog.
43:141–154. 2005.PubMed/NCBI
|
|
4
|
Wojnarowicz PM, Provencher DM, Mes-Masson
AM and Tonin PN: Chromosome 17q25 genes, RHBDF2 and CYGB, in
ovarian cancer. Int J Oncol. 40:18656–1880. 2012.PubMed/NCBI
|
|
5
|
TCGA: Integrated genomic analyses of
ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
|
|
6
|
Gorringe KL, George J, Anglesio MS, et al:
Copy number analysis identifies novel interactions between genomic
loci in ovarian cancer. PloS One. 5:e114082010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pieretti M, Cavalieri C, Conway PS,
Gallion HH, Powell DE and Turker MS: Genetic alterations
distinguish different types of ovarian tumors. Int J Cancer.
64:434–440. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sangha N, Wu R, Kuick R, et al:
Neurofibromin 1 (NF1) defects are common in human ovarian serous
carcinomas and co-occur with TP53 mutations. Neoplasia.
10:1362–1372. 2008.PubMed/NCBI
|
|
9
|
Feng Q, Deftereos G, Hawes SE, et al: DNA
hypermethylation, Her-2/neu overexpression and p53 mutations in
ovarian carcinoma. Gynecol Oncol. 111:320–329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rathi A, Virmani AK, Schorge JO, et al:
Methylation profiles of sporadic ovarian tumors and nonmalignant
ovaries from high-risk women. Clin Cancer Res. 8:3324–3331.
2002.PubMed/NCBI
|
|
11
|
Pergolizzi R, Appierto V, Crosti M, et al:
Role of retinoic acid receptor overexpression in sensitivity to
fenretinide and tumorigenicity of human ovarian carcinoma cells.
Int J Cancer. 81:829–834. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bruening W, Prowse AH, Schultz DC,
Holgado-Madruga M, Wong A and Godwin AK: Expression of OVCA1, a
candidate tumor suppressor, is reduced in tumors and inhibits
growth of ovarian cancer cells. Cancer Res. 59:4973–4983.
1999.PubMed/NCBI
|
|
13
|
Presneau N, Mes-Masson AM, Ge B,
Provencher D, Hudson TJ and Tonin PN: Patterns of expression of
chromosome 17 genes in primary cultures of normal ovarian surface
epithelia and epithelial ovarian cancer cell lines. Oncogene.
22:1568–1579. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wojnarowicz PM, Breznan A, Arcand SL, et
al: Construction of a chromosome 17 transcriptome in serous ovarian
cancer identifies differentially expressed genes. Int J Gynecol
Cancer. 18:963–975. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cody NA, Ouellet V, Manderson EN, et al:
Transfer of chromosome 3 fragments suppresses tumorigenicity of an
ovarian cancer cell line monoallelic for chromosome 3p. Oncogene.
26:618–632. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Quinn MC, Filali-Mouhim A, Provencher DM,
Mes-Masson AM and Tonin PN: Reprogramming of the transcriptome in a
novel chromosome 3 transfer tumor suppressor ovarian cancer cell
line model affected molecular networks that are characteristic of
ovarian cancer. Mol Carcinog. 48:648–661. 2009. View Article : Google Scholar
|
|
17
|
Coss MC, Winterstein D, Sowder RC II and
Simek SL: Molecular cloning, DNA sequence analysis, and biochemical
characterization of a novel 65-kDa FK506-binding protein (FKBP65).
J Biol Chem. 270:29336–29341. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng B, MacDonald JR, Bann JG, et al:
Chicken FK506-binding protein, FKBP65, a member of the FKBP family
of peptidylprolyl cis-trans isomerases, is only partially inhibited
by FK506. Biochem J. 330:109–114. 1998.PubMed/NCBI
|
|
19
|
Patterson CE, Abrams WR, Wolter NE,
Rosenbloom J and Davis EC: Developmental regulation and coordinate
reexpression of FKBP65 with extracellular matrix proteins after
lung injury suggest a specialized function for this endoplasmic
reticulum immunophilin. Cell Stress Chaperones. 10:285–295. 2005.
View Article : Google Scholar
|
|
20
|
Patterson CE, Schaub T, Coleman EJ and
Davis EC: Developmental regulation of FKBP65. An ER-localized
extra-cellular matrix binding-protein. Mol Biol Cell. 11:3925–3935.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishikawa Y, Vranka J, Wirz J, Nagata K and
Bachinger HP: The rough endoplasmic reticulum-resident
FK506-binding protein FKBP65 is a molecular chaperone that
interacts with collagens. J Biol Chem. 283:31584–31590. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Forbes SA, Bindal N, Bamford S, et al:
COSMIC: mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic Acid Res. 39:D945–D950. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alanay Y, Avaygan H, Camacho N, et al:
Mutations in the gene encoding the RER protein FKBP65 cause
autosomal-recessive osteogenesis imperfecta. Am J Hum Genet.
86:551–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kelley BP, Malfait F, Bonafe L, et al:
Mutations in FKBP10 cause recessive osteogenesis imperfecta and
Bruck syndrome. J Bone Miner Res. 26:666–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishida T, Oda T, Sugiyama T, Izumi S and
Yakushiji M: Concurrent ovarian serous carcinoma and osteogenesis
imperfecta. Arch Gynecol Obstet. 253:153–156. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ouellet V, Zietarska M, Portelance L, et
al: Characterization of three new serous epithelial ovarian cancer
cell lines. BMC Cancer. 8:1522008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Le Page C, Marineau A, Bonza PK, et al:
BTN3A2 expression in epithelial ovarian cancer is associated with
higher tumor infiltrating T cells and a better prognosis. PloS One.
7:e385412012.PubMed/NCBI
|
|
28
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
29
|
Ouellet V, Provencher DM, Maugard CM, et
al: Discrimination between serous low malignant potential and
invasive epithelial ovarian tumors using molecular profiling.
Oncogene. 24:4672–4687. 2005. View Article : Google Scholar
|
|
30
|
Rozen S and Skaletsky H: Primer3 on the
WWW for general users and for biologist programmers. Methods Mol
Biol. 132:365–386. 2000.PubMed/NCBI
|
|
31
|
Karolchik D, Baertsch R, Diekhans M, et
al: The UCSC Genome Browser Database. Nucleic Acid Res. 31:51–54.
2003. View Article : Google Scholar
|
|
32
|
Arcand SL, Maugard CM, Ghadirian P, et al:
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French
Canadian breast cancer families. Breast Cancer Res Treat.
108:399–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Davis EC, Broekelmann TJ, Ozawa Y and
Mecham RP: Identification of tropoelastin as a ligand for the 65-kD
FK506-binding protein, FKBP65, in the secretory pathway. J Cell
Biol. 140:295–303. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Salvador S, Gilks B, Kobel M, Huntsman D,
Rosen B and Miller D: The fallopian tube: primary site of most
pelvic high-grade serous carcinomas. Int J Gynecol Cancer.
19:58–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Henriksen R, Sorensen FB, Orntoft TF and
Birkenkamp-Demtroder K: Expression of FK506 binding protein 65
(FKBP65) is decreased in epithelial ovarian cancer cells compared
to benign tumor cells and to ovarian epithelium. Tumour Biol.
32:671–676. 2011. View Article : Google Scholar
|
|
36
|
Provencher DM, Lounis H, Champoux L, et
al: Characterization of four novel epithelial ovarian cancer cell
lines. In Vitro Cell Dev Biol Anim. 36:357–361. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Birch AH, Quinn MC, Filali-Mouhim A,
Provencher DM, Mes-Masson AM and Tonin PN: Transcriptome analysis
of serous ovarian cancers identifies differentially expressed
chromosome 3 genes. Mol Carcinog. 47:56–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cody NA, Shen Z, Ripeau JS, et al:
Characterization of the 3p12.3-pcen region associated with tumor
suppression in a novel ovarian cancer cell line model genetically
modified by chromosome 3 fragment transfer. Mol Carcinog.
48:1077–1092. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Manderson EN, Birch AH, Shen Z, Mes-Masson
AM, Provencher D and Tonin PN: Molecular genetic analysis of a cell
adhesion molecule with homology to L1CAM, contactin 6, and
contactin 4 candidate chromosome 3p26pter tumor suppressor genes in
ovarian cancer. Int J Gynecol Cancer. 19:513–525. 2009. View Article : Google Scholar
|
|
40
|
Kobel M, Kalloger SE, Boyd N, et al:
Ovarian carcinoma subtypes are different diseases: implications for
biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schauer IG, Sood AK, Mok S and Liu J:
Cancer-associated fibroblasts and their putative role in
potentiating the initiation and development of epithelial ovarian
cancer. Neoplasia. 13:393–405. 2011.PubMed/NCBI
|
|
42
|
Finak G, Bertos N, Pepin F, et al: Stromal
gene expression predicts clinical outcome in breast cancer. Nat
Med. 14:518–527. 2008. View
Article : Google Scholar : PubMed/NCBI
|
